Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA Depot phase III placebo-controlled trial in relapsing forms of multiple sclerosis
2018-000284-93Phase 3Completed
- Sponsor
- Mapi Pharma
- Start
- Oct 2019
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) and multiple sclerosis (MS) comparing GA Depot with Placebo (2 arms). Primary endpoint: Annualized Relapse Rate. Started Oct 2019; status: completed.
02
Drugs
glatiramer acetate depot
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-000284-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000284-93.